47 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27994738	50	Sulfonamides as Selective Na	Amgen
26985315	49	Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.	Xenon Pharmaceuticals
25927480	36	Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications.	Merck Research Laboratories
26101568	51	Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain.	Pfizer
25658507	218	Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel.	Amgen
24601592	48	Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.	University College London
23121096	86	Ion channels as therapeutic targets: a drug discovery perspective.	Pfizer
17483457	58	A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.	Abbott Laboratories
18243692	85	Imidazopyridines: a novel class of hNav1.7 channel blockers.	Merck Research Laboratories
18176998	45	Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.	Abbott Laboratories
17804230	1	Novel steroidal saponins, Sch 725737 and Sch 725739, from a marine starfish, Novodinia antillensis.	Schering-Plough Research Institute
21634377	73	Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.	Amgen
21106456	35	Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain.	Merck Research Laboratories
20965738	78	Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain.	Abbott Laboratories
20855211	91	Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.	Abbott Laboratories
18501613	31	Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.	Abbott Laboratories
17489575	7	Sodium channel blockers.	Purdue Pharma
32392056	108	Discovery of DS-1971a, a Potent, Selective Na	Daiichi Sankyo
27441383	117	Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.	Amgen
30538065	48	The discovery and optimization of benzimidazoles as selective Na	Pfizer
31012583	128	Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform Na	Siteone Therapeutics
25060923	44	Recent progress in sodium channel modulators for pain.	Pfizer
30346167	71	Discovery of Tarantula Venom-Derived Na	Amgen
28629594	55	The discovery of benzoxazine sulfonamide inhibitors of Na	Amgen
28682065	133	Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na	Icagen
11438309	51	The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.	Janssen Research Foundation
8996185	121	Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.	SynthÉLabo Recherche
8935801	586	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.	Janssen Research Foundation
8564266	77	Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.	Vrije Universiteit
1501121	12	Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist.	Sanofi Recherche